Suppr超能文献

术前肿瘤异常蛋白是预测根治性切除术后肝细胞癌肿瘤学结局的有前途的生物标志物。

Preoperative tumor abnormal protein is a promising biomarker for predicting hepatocellular carcinoma oncological outcome following curative resection.

机构信息

Department of Hepatopancreatobiliary Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.

Department of Medical Imaging, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.

出版信息

J Cancer Res Ther. 2022 Dec;18(7):2021-2026. doi: 10.4103/jcrt.jcrt_58_22.

Abstract

INTRODUCTION AND OBJECTIVES

The objective of this study was to explore the potential relationship between tumor abnormal protein (TAP) and the prognosis of hepatocellular carcinoma (HCC) after a radical hepatectomy.

PATIENTS OR MATERIALS AND METHODS

This retrospective study included 168 HCC patients (tumor recurrence in 78 patients) who underwent a curative resection from January 2018 to June 2020. The whole population was categorized into a TAP high (≥224.6 μm) or a TAP low group (<224.6 μm).

RESULTS

There was no correlation between maximum tumor size and TAP. In the whole population or subgroups stratified by maximum tumor size, the recurrence-free survival (RFS) rate of the TAP low group was significantly higher than TAP high group (P < 0.05 for all). The multivariate analysis revealed that TAP (hazard ratio [HR], 3.47; 95% confidence interval [CI], 2.18-5.51; P < 0.001), large tumor size (HR, 2.18; 95% CI, 1.36-3.49; P < 0.001), poor tumor differentiation (HR, 0.53; 95% CI, 0.33-0.84; P = 0.007), and presence of microvascular invasion (MVI) (HR, 2.03; 95% CI, 1.28-3.22; P = 0.003) were independently associated with RFS. The prognostic implication of the nomogram incorporating TAP, maximum tumor diameter, tumor differentiation, and MVI was stronger than the model without TAP.

CONCLUSION

The present study suggests that higher preoperative TAP is correlated with undesirable prognosis in HCC patients who underwent a radical hepatectomy. Our study provides a robust nomogram for RFS of postoperative HCC patients.

摘要

简介和目的

本研究旨在探讨肿瘤异常蛋白(TAP)与根治性肝切除术后肝细胞癌(HCC)预后之间的潜在关系。

患者或材料和方法

本回顾性研究纳入了 2018 年 1 月至 2020 年 6 月期间接受根治性切除术的 168 例 HCC 患者(肿瘤复发 78 例)。将所有患者分为 TAP 高(≥224.6μm)或 TAP 低(<224.6μm)组。

结果

最大肿瘤直径与 TAP 之间无相关性。在全人群或按最大肿瘤直径分层的亚组中,TAP 低组的无复发生存率(RFS)明显高于 TAP 高组(所有 P<0.05)。多因素分析显示,TAP(风险比[HR],3.47;95%置信区间[CI],2.18-5.51;P<0.001)、大肿瘤直径(HR,2.18;95%CI,1.36-3.49;P<0.001)、肿瘤分化不良(HR,0.53;95%CI,0.33-0.84;P=0.007)和微血管侵犯(MVI)(HR,2.03;95%CI,1.28-3.22;P=0.003)是 RFS 的独立相关因素。纳入 TAP、最大肿瘤直径、肿瘤分化和 MVI 的列线图的预后意义强于不包括 TAP 的模型。

结论

本研究表明,术前 TAP 升高与接受根治性肝切除术的 HCC 患者预后不良相关。我们的研究为术后 HCC 患者的 RFS 提供了一个强大的列线图。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验